Internship

Field Operations Incentive Compensation Intern

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Pursuing an undergraduate or graduate degree with an interest in biotechnology
  • Specific degree or field required: Finance, Accounting, or Similar degree
  • Comfortable reviewing and analyzing large data sets.
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Interest in attending various program events, including social gatherings, career development workshops, and more
  • Ability to commit to a 10-week, full-time summer program
Responsibilities
  • Supporting a range of activities, including data analysis and insights
  • Understand existing data models and connecting disparate data sources
  • Identifying patterns and challenging perceptions (what does the data say?)
  • Presenting findings and interacting with commercial leadership within the company
  • Collaborating with a mentor team of cross-functional team members as well as the other interns in the class
  • Completing a special project and presenting the recommendations to senior management upon completion
Desired Qualifications
  • Prior experience in the pharmaceutical or biotechnology industry would be an asset but is not required
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is an asset but is not required
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY's FDA approval marks a significant advancement in CAH treatment.
  • Collaboration with Nxera Pharma strengthens Neurocrine's position in neuropsychiatric therapeutics.
  • Participation in major healthcare conferences boosts Neurocrine's visibility and investor relations.

What critics are saying

  • Increased competition in muscarinic agonist market may impact Neurocrine's market share.
  • Reliance on PANTHERx Rare for distribution poses potential partnership risks.
  • High cost of CRENESSITY could limit patient accessibility and market penetration.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's muscarinic agonist portfolio targets innovative treatments for neuropsychiatric disorders.
  • Partnership with Pantherx® Rare enhances patient access to rare disease treatments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays